Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Genmab logo — Differentiated human antibody therapeutics for the treatment...

Genmab

Differentiated human antibody therapeutics for the treatment of cancer

Founded 1999 Denmark Denmark 2981 employees IPO Total: $2.28B Biotechnology, Pharmaceutical

General Information

Company Name Genmab
Founded Year 1999
Location Denmark Denmark +7
Founders / Decision Makers
Team member Team member
Employees 2981
Industries Biotechnology, Pharmaceutical
Funding Stage IPO
Social

Get notified when Genmab moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

AI Insight

Bounce Watch AI
2 months ago

Genmab is strategically expanding its global footprint by appointing new leadership to spearhead growth in Asia Pacific and other international markets. This geographical expansion is complemented by ongoing clinical development successes, highlighted by shared trial data with partner AbbVie, underscoring their commitment to advancing their late-stage pipeline. The company is also actively enhancing its market presence and communication through participation in key industry events and significant website updates.

Signal Types
Expansion Partnership Marketing Digital Activity
Strategic Labels
International Expansion Strategic Partnerships Market Engagement
Next Move: Market Entry
·
Impact: 7/10
·
Ideal For: Biopharma Growth Investors — Post-IPO

About Genmab

Genmab, founded in 1999, is a pioneering international biotechnology company headquartered in Denmark. Renowned for its expertise in antibody innovation, Genmab focuses on developing differentiated human antibody therapeutics aimed at treating cancer and other serious diseases. Through its innovative approach, the company has spearheaded advancements in antibody-based formats, including bispecific antibodies and antibody-drug conjugates.

With a strong commitment to transforming science into medicine, Genmab is advancing its robust late-stage clinical pipeline, comprising both wholly owned and partnership programs. This effort is aligned with their slogan, "Differentiated human antibody therapeutics for the treatment of cancer." The company's core values encapsulate passion for innovation, integrity, teamwork, and a commitment to creating a supportive work environment.

As of their latest financial move, Genmab secured a $51.50M post-IPO equity investment on 01 November 2025, marking a significant milestone for the company's growth and its mission to deliver transformative medical solutions globally.

Taxonomy: Antibody Therapeutics, Cancer Treatment, Bispecific Antibodies, Antibody-Drug Conjugates, Immune-Modulating Antibodies, Clinical Pipeline, Innovative Medicines, Antibody Innovation, Late-stage Clinical Trials, Biopharmaceuticals, Healthcare Innovation, Unmet Medical Needs, Drug Development

Services & Products

Development of Antibody Therapeutics
Pipeline of Medicines
Biotech Research

Target Customers

Healthcare Professionals Patients & Care Partners Investors Corporate Partners

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Post Ipo Equity •••••• - 01 Nov 2025
IPO •••••• - 01 Jul 2019
Post Ipo Equity •••••• - 01 Jul 2010
Post Ipo Equity •••••• 1 •••• •••• 01 Oct 2009
Early VC •••••• - 01 Jun 2000

View All 6 Funding Rounds

Genmab Alternatives & Competitors

View All Alternatives
Genmab vs
Planet Biotechnology, Inc.
Planet Biotechnology, Inc.

Developing promising antibodies and receptor/ligand-Fc fusion proteins for the treatment and prevent...

Debt Financing
5 employees
Biotechnology, Health and Wellness
Compare Genmab vs Planet Biotechnology, Inc.
Genmab vs
Visterra Inc.
Visterra Inc. United States

We bring better biologics to life. Biospace Best Place to Work 2024!

Series C
139 employees
Biotechnology, Health Care
Compare Genmab vs Visterra Inc.
Genmab vs
Klus Pharma Inc.
Klus Pharma Inc. United States

Discovery and development of novel and safer antibody-based therapeutics.

11 employees
Manufacturing, Pharmaceutical
Compare Genmab vs Klus Pharma Inc.
View all alternatives

FAQ About Genmab

Differentiated human antibody therapeutics for the treatment of cancer
Genmab was founded in 1999.
Genmab is headquartered in Denmark.
Genmab operates in the following industries: Biotechnology, Pharmaceutical.
Genmab has approximately 2981 employees.
Genmab has completed 6 funding rounds, raising a total of $2.28B. The latest funding stage is IPO.
Genmab offers: Development of Antibody Therapeutics, Pipeline of Medicines, Biotech Research.
Top alternatives and competitors to Genmab include Planet Biotechnology, Inc., Visterra Inc., Klus Pharma Inc., Xencor, Arch Oncology. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Genmab and Planet Biotechnology, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Genmab and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy